Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + CAV/IE in Advanced/Unresectable Bone and Soft Tissue Sarcoma
NCT04589741Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2020
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in soft tissue sarcoma (STS), bone sarcoma, sponsored by Sun Yat-sen University. Started Oct 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT04589741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589741.